Bio Key International INC Form 4 insider transactions

James David Sullivan, Chief Legal Officer and SVP Strategy & Compliance at BIO-key International, acquired 250 shares of common stock under an employee stock purchase plan.

Michael DePasquale, CEO of Bio-Key International, acquired 250 shares of common stock through an employee stock purchase plan.

BIO-key International's Chief Technology Officer, Mira LaCous, acquired shares through an employee stock purchase plan.

BIO-key International's Chief Technology Officer, Mira Lacous, acquired 2,500 shares of common stock at $0.46 per share through an employee stock purchase plan.

BIO-key International's Chief Legal Officer, James D. Sullivan, acquired 2,500 shares of common stock at $0.46 per share through an employee stock purchase plan.

BIO-key International CEO Michael W. DePasquale acquired 2,500 shares of common stock at $0.46 per share through the company's Employee Stock Purchase Plan.

BIO-KEY International CEO Michael W. DePasquale reported additional common stock purchases, increasing his direct beneficial ownership to 102,775 shares.

BIO-KEY International CEO Michael W. DePasquale increased his direct ownership of common stock through open market purchases on September 15 and 16, 2025.

BIO-KEY International's Chief Financial Officer, Cecilia C. Welch, was granted 35,000 shares of restricted common stock under the company's 2023 Stock Incentive Plan.

BIO-KEY International's Chief Legal Officer, James David Sullivan, was granted 40,000 restricted common shares under the company's 2023 Stock Incentive Plan.

BIO-KEY International's Chief Technology Officer, Mira K. Lacous, has reported a planned acquisition of 25,000 restricted common shares under a Rule 10b5-1(c) plan.

BIO-KEY International's CEO and Chairman, Michael W. DePasquale, was granted 45,000 shares of restricted common stock under the company's 2023 Stock Incentive Plan.

BIO-KEY International's Chief Legal Officer, James D. Sullivan, acquired 10,000 shares of common stock at $0.77 per share.

Michael W. DePasquale, CEO and Chairman of BIO-key International, Inc., acquired 139 shares of common stock through the company's Employee Stock Purchase Plan.

James David Sullivan, Chief Legal Officer and SVP Strategy & Compliance at BIO-key International, Inc., acquired 139 shares of common stock through the company's Employee Stock Purchase Plan.

BIO-key International's Chief Technology Officer, Mira K. LaCous, acquired 139 shares of common stock at $0.70 per share through the company's Employee Stock Purchase Plan.

BIO-key International's CEO and Chairman, Michael W. DePasquale, has increased his direct ownership in the company by purchasing 5,000 shares of common stock at $0.78 per share.

BIO-key International's Chief Executive Officer and Chairman, Michael W. DePasquale, has acquired 4,000 shares of common stock at $0.83 per share through a pre-planned transaction.

Michael W. DePasquale, CEO and Chairman of BIO-KEY International Inc., has acquired 5,000 shares of the company's common stock at $0.81 per share, increasing his direct beneficial ownership to 44,519 shares.

Kwok Fong Wong, a Director and Managing Director of BIO-key HK, was granted 2,000 shares of restricted common stock under the company's 2023 Stock Incentive Plan.

Emmanuel Alia, a Director at BIO-KEY International Inc., was granted 5,000 shares of restricted common stock on May 27, 2025, as part of the company's 2023 Stock Incentive Plan.

BIO-KEY International, Inc. Director Robert J. Michel reported the acquisition of 6,266 shares of common stock through the company's 2023 Stock Incentive Plan, including restricted stock and shares for board meeting fees.

Cameron E. Williams, a Director at BIO-KEY International Inc., acquired 6,266 shares of common stock through restricted stock grants and compensation for board services, increasing his direct beneficial ownership to 21,950 shares.

Director Cameron E. Williams acquired 3,897 shares of Bio-Key International stock as compensation for board meeting attendance fees.

Emmanuel Alia, a director at Bio-Key International, acquired 3,897 shares of common stock on May 8, 2025, as payment for board meeting attendance fees.

Robert J. Michel, a director at Bio-Key International, acquired 3,897 shares of common stock as payment for board meeting attendance fees.

Director Cameron E. Williams receives 2,971 shares of Bio-Key International as payment for board meeting attendance fees.

Emmanuel Alia, a director at Bio-Key International, acquired 2,971 shares of common stock on March 20, 2025, as payment for board meeting attendance fees.

Robert J. Michel, a director at Bio-Key International, acquired 2,971 shares of common stock on March 20, 2025, as payment for board meeting attendance fees.

Mira LaCous, Chief Technology Officer of Bio-Key International, acquired 139 shares of common stock under the company's Employee Stock Purchase Plan on December 31, 2024.